For most antivenoms there is little information from clinical studies to infer the relationship between dose and efficacy or dose and toxicity. Antivenom dose-finding studies usually recruit too few patients (e.g. less than 20) relative to clinically significant event rates (e.g. 5%). Model based adaptive dose-finding studies make efficient use of accrued patient data by using information across dosing levels, and converge rapidly to the contextually defined 'optimal dose'. Adequate sample sizes for adaptive dose-finding trials can be determined by simulation studies.
48
across dosing levels, and therefore they have limited ability to rapidly identify the 49 desired optimal dose with high confidence [17] . Second, model based designs which do 50 require determining a parametric relationship (model) between the dose and the 51 outcome, termed a dose-response model [18] . The continual reassessment method [19] 52 was the first proposed model based design for dose-finding. Data from sequentially [20] , rule-based designs have been the dominant choice. Fewer than 1 in 59 10 trials in oncology -where dose-finding is critical -have used a model based 60 approach [21, 22] , mostly due to perceived difficulty of implementation and lack of 61 understanding of the methods [23] . 62 This paper presents a novel phase 2 type, model based, Bayesian adaptive design to 63 determine optimal antivenom dosing for Russell's viper envenoming. In this context 64 there are two concurrent considerations for dose optimality. Firstly, the efficacy of the 65 dose, defined in this context as restoration of blood coagulation within 6 hours; 66 secondly, the dose-related toxicity, defined as the occurrence of an anaphylactic reaction 67 within 180 minutes post antivenom administration. The model based design estimates 68 dose-response curves for both the efficacy outcome and the toxicity outcome, and thus 69 derives a contextually defined 'optimal dose'. The particularities of the design reported 70 here were tailor-made for a dose-finding trial in Daboia siamensis envenoming but the 71 design generalises to any systemic envenoming with clinically relevant endpoints 72 whereby the efficacy and toxicity outcomes are both binary, e.g. [13, 24, 25] . We compare 73 the in silico performance of this design against that of a tailor-made rule based design 74 (modified '3+3' design) under multiple simulation scenarios. 75 
Methods

76
Literature review of antivenom dose-finding trials 77 A systematic review of the literature relating to dose-finding trials of antivenom was 78 performed using the Medline medical database. The following keywords "antiven*" and 79 "dose-finding" or "clinical trial" were used and searched for on 01/11/2019. Only papers 80 reporting a comparative trial of two or more doses of the same antivenom were included. 81 Papers reporting pre-clinical trials and studies comparing two or more different 82 February 1, 2020 3/21 antivenoms were excluded. Referenced articles in the articles identified by the search 83 were assessed for suitability and included if they met the outlined criteria. The final set 84 of studies reviewed are shown in Supplementary Table S1 . 85 A dose-finding trial in Daboia siamensis envenoming, Myanmar 86
The primary objective of our proposed study is to determine the optimal initial dose of 87 the novel BPI lyophilised viper antivenom. The secondary objectives are to assess the 88 relationship between the baseline venom concentration and the clinical outcomes, the 89 sensitivity and specificity of the 20 minute whole blood clotting time (20WBCT) at 90 detecting coagulopathy, the presence of ferryl-haem derivatives in the urine and the 91 envenoming sequelae. Patients will be consented to participate if they present with a 92 history of Daboia siamensis envenoming, are antivenom naive, aged ≥16 years and have 93 a positive 20WBCT. Patients with a known coagulopathy will be excluded. All 94 participants will have a serum venom assay to confirm envenoming performed 95 retrospectively. Enrolled participants will be randomised to receive either standard of 96 care (80 mL) or an adaptively chosen dose. Aside from the initial dosing of antivenom, 97 patients in each group will be managed according to Myanmar national guidelines [11] . 98 Participants will be invited to attend follow up at 1 week and 3 months after discharge. 99 This trial is registered at ClinicalTrials.gov with identifier number NCT04210141.
100
At the start of the trial, the optimal dose will be defined as the dose which either (i) 101 restores blood coagulability at 6 hours in 95% of patients (efficacy endpoint), or (ii) 102 causes anaphylaxis in 5% of patients (toxicity endpoint), whichever is lower. Both of 103 these thresholds are subjective and were chosen after consultation with local clinicians 104 and snakebite experts. The ambitious threshold of 95% for efficacy was deemed 105 appropriate for Daboia siamensis envenoming as delays in venom reversal increase the 106 incidence of acute kidney injury [26] . In snake-bite envenoming involving species where 107 the time of venom reversal is less critical, a lower efficacy threshold for initial dosing 108 may be more appropriate. The reason for choosing an upper bound for the efficacy 109 (here 95%) is that it is likely that the efficacy will plateau at higher doses. It is possible 110 that an unknown proportion of patients will not meet the 6 hour efficacy endpoint as a 111 result of delayed absorption of some venom components [27] . Higher initial doses of 112 antivenom may not solve this issue. These target efficacy and toxicity thresholds may 113 not be the most appropriate for the context of Russell's viper envenoming in Myanmar. 114 After recruitment of 50 and then 100 patients, we will perform full interim analyses and 115 subsequently, in consultation with the Data and Safety Monitoring Board, update the 116 target efficacy and target toxicity trial design parameters. For example, it may become 117 apparent that 95% target efficacy is too high and that more than 5% of patients will not 118 have restored coagulation at 6 hours regardless of the dose. This interim analysis will 119 allow for a re-adjustment of the trial parameters which decide the contextual target 120 optimal dose.
121
The definition of efficacy for the purposes of this trial only pertains to the initial 122 dose of antivenom. An efficacious dose is defined as restoring blood coagulability by 6 123 hours post administration as measured by the 20WBCT (a binary outcome). In case of 124 treatment failure at 6 hours, all repeat doses will be equal to the initial dose 125 administered. The total number of doses needed or the total time to restoration of 126 coagulability will not be taken into account for the primary efficacy outcome for the 127 adaptive design. The primary outcome used for determining toxicity of the initial dose 128 is the occurrence of an anaphylactic reaction within 180 minutes of antivenom 129 administration, as described by Sampson et al and accepted by the European Academy 130 of Allergy and Clinical Immunology [28] .
131
Only patients with 'non-severe' systemic envenoming will be invited to participate in 132 the model based adaptive design study. Severely envenomed patients (who are estimated to represent 15% of envenomed patients) will be invited to participate in a 134 parallel observational study. Patients enrolled with non-severe envenoming will be 135 randomized, at a 1:4 ratio, to either (i) the standard of care dose of antivenom (80 mL), 136 or (ii) an adaptively chosen dose. The starting dose for the adaptive arm (120 mL) was 137 determined using prior information for the new antivenom. Participants and study 138 doctors will not be blinded to treatment dose. All antivenom used in the study will be 139 provided from a single batch. The antivenom will undergo retrospective pre-clinical 140 testing to determine the median effective dose (ED50), the gold standard pre-clinical 141 test for assessing antivenom efficacy [29, 30] . This will allow comparison between 142 pre-clinical testing and in vivo outcomes.
143
The pragmatic addition of randomisation in this design is to ensure that the dosing 144 range includes those recommended by current national guidelines which is the reference 145 standard. This will allow for a non-model dependent comparison between the adaptively 146 determined 'optimal' dose and the current national guidelines. This section outlines the approach for assigning an initial antivenom dose to each 150 patient randomised to the adaptive arm. This adaptive assignment will depend on (i) 151 the parametric dose-response models of toxicity and efficacy; (ii) the prior distribution 152 over the model parameters; (iii) the toxicity and efficacy data observed for the 153 antivenom thus far. In particular, the dose-efficacy and dose-toxicity models will be 154 updated with data from both the standard of care arm and the adaptive arm.
155
Patients are enrolled in successive cohorts of a pre-specified size N cohort ≥ 1.
156
Randomisation is performed at the individual level. We assume that the toxicity and 157 efficacy outcomes for all previously enrolled cohorts of patients are known by the time 158 each new cohort of patients is enrolled. The trial design necessitates determining values 159 for the following parameters. The starting dose V 0 is the dose given to the first patient 160 randomised to the adaptive arm (120 mL in our trial). When escalating to doses not 161 previously administered, we need to determine a maximum dose increment δ v (this is 10 162 mL in our trial, the volume of one vial). In order to determine the optimal dose, we 163 must define a maximum tolerated toxicity (MTT), and a target efficacy level (TEL).
164
The dose estimated by the model to have an average toxicity equal to the MTT is 165 denoted the maximum tolerated dose (MTD); and the dose estimated by the model to 166 have an average efficacy equal to the TEL is denoted the target efficacious dose (TED). 167 The optimal dose is then defined as: V * = min (MTD, TED).
168
Additional parameters in the trial could include a minimum dose (the adaptively 169 chosen dose cannot go below this dose); a maximum dose (the adaptively chosen dose 170 cannot go above this dose); a 'burn-in' period for the adaptive arm. If a minimum or a 171 maximum dose are defined then these should be put into context with respect to the 172 starting dose, the maximum dose increment or decrement and the total sample size.
173
The purpose of a burn-in period for the adaptive arm is to reduce stochasticity at the 174 start of the trial, especially in the context of weakly informative prior distributions over 175 the model parameters. For example, a burn-in of 20 patients would imply that the 176 adaptive arm would only be updated after the first 20 patients had been enrolled 177 (irrespective of how they were randomised).
178
In addition, it is possible to specify stopping rules for the trial. For example, 179 randomisation to the control arm (standard of care dose) could be stopped once 180 sufficient evidence had be accrued of its inferiority (either too low and thus inferior 181 efficacy, or too high and thus inferior due to increased toxicity) in comparison to the 182 current adaptive dose. We would recommend the use of a non-parameteric test (e.g.
183
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Fisher's exact test), with appropriate adjustment for multiple testing.
184
At each step of the model update, it is possible to either use all the available accrued 185 data or only the data from the adaptive arm. Under model mis-specification, whereby 186 the models of the dose-response relationships are not in agreement with the true, 187 unknown dose-response relationships, it may in fact be sub-optimal to use all the data. 188 The reason is that the model specification (for example, a single parameter model) may 189 be a good local approximation of the true underlying dose-response, but may be a poor 190 overall approximation. If this were the case, then only using data from doses close to the 191 target dose will provide a better approximation than using all the doses including doses 192 substantially below the target dose. We do not believe that this is a concern in the setup 193 here as we use a mechanistically derived and flexible two parameter dose-response model 194 for the efficacy. Nor is this a concern for the toxicity model as the adaptively assigned 195 doses will, in expectation be less than the MTT which is usually low (less than 10%). antivenom acts. We assume that there is a fixed linear relationship between the volume 201 of venom in the body (which is unknown) and the dose of antivenom needed to 202 neutralise all the circulating venom. If we assume that the distribution of the total mass 203 of venom injected is approximately normal, then the efficacy dose-response curve follows 204 a normal cumulative distribution with mean µ and standard deviation σ. The 205 parameter µ corresponds to an efficacious dose of antivenom in 50% of patients. The 206 value of 1.64σ determines the dose increase necessary to obtain an efficacy of 207 approximately 95%. Weakly informative priors can be set for both these parameters. 208 We choose to model the dose-toxicity relationship using a logistic function, where 209 the dose is modelled on the logarithmic scale (base 2 for visual purposes, this does not 210 impact the statistical inference). This is equivalent to fitting a Bayesian logistic 211 regression model to the toxicity outcomes. This toxicity dose-response model has two 212 independent parameters: an intercept term which we denote α tox , and a slope term for 213 the log 2 dose which we denote β tox . The exact mathematical specification is given in 214 Supplementary Text . Under the logistic function parameterisation of the toxicity 215 dose-response model, it is possible to interpret the parameters of the model as follows. 216 The intercept term α tox corresponds to the expected toxicity after administration of one 217 unit of antivenom.
218
A modified '3+3' rule based design 219 In order to illustrate the advantages and disadvantages of model based adaptive designs, 220 we compared the in silico performance of our model based adaptive design with that of 221 a modified '3+3' rule based design. As in our model based design, patients are recruited 222 in cohorts of size N cohort . This is set to 3 in the classic '3+3' design, but in our case is a 223 trial design parameter. The rule based design does not make parametric assumptions 224 about the relationship between the dose and the outcomes. For each dose v trialled, a 225 dose-dependent frequentist estimate of toxicity,θ tox v , and a dose-dependent frequentist 226 estimate of efficacy,θ eff v , are calculated. Based on these estimates, the dose is 227 subsequently increased, decreased, or remains the same for the next N cohort patients,
228
according to a pre-specified set of rules and trial design parameters (the MTT and the 229 TEL). Our rule based design is a type of cumulative cohort design [31] as it uses all the 230 data from previous patients recruited to a particular dosing level. The traditional '3+3' 231 design is memory-less (only uses information from the previous cohort). However, we refer to our rule based design as a modified '3+3' as this nomenclature is known more 233 widely.
234
In order for the two designs to be comparable, we use the same values for the MTT 235 and TEL as in the model based design. We also use the same randomisation ratio 236 between the adaptive arm and the standard of care arm. 237 We use the following rules for dose escalation and de-escalation: 238 1. If fewer than 20 patients have received dose v:
2. If 20 or more patients have received dose v:
The free parameter gives the tolerance level around the target efficacious dose. In the 251 simulation studies, we set it equal to 1% point difference. The differentiation based on 252 20 patients is due to the choice of MTT and TEL which are 5% and 95%, respectively. 253 Only after giving a dose v to 20 patients or more is it possible for the frequentist 254 estimate to discriminate whether 0 <θ tox v ≤ MTT. This will reduce stochasticity during 255 the recruitment of the first 20 patients.
256
A '3+3' type design has been used previously to identify candidate antivenom doses 257 for treatment of envenoming by saw-scaled or carpet vipers (Echis ocellatus) [24] . 258 However, the rules outlined in [24] were ambiguous. We note that the design was for 259 very small sample sizes (at most 6 per dosing level). We argue that small sample sizes 260 do not allow for an accurate identification of the MTD or the TED when target event 261 rates are 5% or 95%. Thus our proposed modification is a more appropriate comparator 262 design for the performance of the model based design.
263
Simulation study 264 We compared the stochastic behaviours of the model based and the rule based designs 265 using a simulation study. Each simulation stopped after the enrolment of 260 patients. 266 The global trial parameters were: N cohort = 3; δ v = 10 mL; the starting dose in the 267 adaptive arm was 120 mL; the standard of care dose was 80 mL; 20% of patients were 268 randomised to the standard of care dose and 80% to the adaptive dose; the minimum 269 assigned dose was set to 10 mL; no maximum dose was specified; the MTT was set to 270 5% and the TEL was set to 95%. No burn-in period was specified.
271
We simulated 2000 independent trials under seven scenarios, whereby each scenario 272 specifies a simulation truth MTD and TED and underlying dose-toxicity and 273 dose-efficacy relationships. In scenarios 1-4 the dose-response models for the model 274 based design were well-specified. For scenarios 5-7 the dose-response models were 275 mis-specified. Scenario 5 simulated data whereby toxicity was dose-independent.
276
Scenarios 6-7 simulated data whereby the venom mass (and therefore the antivenom 277 February 1, 2020 7/21 efficacy) was exponentially distributed. This implies that the distribution of venom 278 mass has a heavier tail than predicted by the normal approximation. In all simulations 279 all data, both from the adaptive and standard of care arms, were used in the model 280 updates.
281
The seven scenarios are as follows: 282 1. The optimal dose is 'toxicity driven', and lower than our prior estimate (120 mL). 283 By 'toxicity driven', we mean that the MTD is strictly less than the TED. In this 284 scenario we choose an MTD of 80 mL, and a TED of 200 mL.
285
2. The optimal dose is 'efficacy driven', and lower than our prior estimate (120 mL). 286 By 'efficacy driven', we mean that the TED is strictly less than the MTD. In this 287 scenario, we chose a TED of 80 mL, and an MTD of 200 mL. 3. The optimal dose is 'toxicity driven', and higher than our prior estimate (120 mL). 289 In this scenario, we choose an MTD of 300 mL, and a TED of 600 mL. 4. The optimal dose is 'efficacy driven', and higher than our prior estimate (120 mL). 291 In this scenario, we chose a TED of 300 mL and an MTD of 600 mL.
292 5. Toxicity is idiosyncratic (dose-independent) and occurs in 15% of patients. The
293
TED is 600 mL. In this scenario, as per our definition, the optimal dose is equal to 294 the minimum dose (10 mL). 295 6. The optimal dose is 'efficacy driven' and lower than our prior estimate (120 mL). 296 The efficacy dose-response curve is mis-specified (venom mass is exponentially 297 distributed) and the TED is approximately 80 mL. The toxicity dose-response 298 curve is well-specified with an MTD of 200 mL. 299 7. The optimal dose is 'efficacy driven' and higher than our prior estimate (120 mL). 300 The efficacy dose-response curve is mis-specified (simulation truth is exponentially 301 distributed) and the TED is approximately 300 mL. The toxicity dose-response 302 curve is well-specified with an MTD of 600 mL.
303
All these simulations are fully reproducible via the code available on github: provided in a modular format to ease adaptation to different contexts.
307
Results
308
Literature review on antivenom dose-finding trials 309 Using the search criteria, 112 abstracts were reviewed for suitability. Sixteen papers 310 were identified as including clinical data relating to two or more doses of antivenom.
311
Studies included a combined total of 1165 envenomed patients from a variety of 312 taxonomic orders (Scorpiones (1), Lepidoptera (1), Hymenoptera (1) and Squamata sub 313 order Serpentes (13)), see Supplementary Table S1 . One paper described a trial 314 protocol for which the results have yet to be published. Five papers investigated new 315 antivenoms with the remaining nine papers investigating established antivenoms. Four 316 papers performed a retrospective review of antivenom doses and 10 studies were 317 conducted/plan to be conducted prospectively. Relating to dose-finding trial design, one 318 paper used a '3+3' dose escalation model [24] while the remaining 13 papers all assessed 319 pre-determined doses. None of the identified studies used a model based adaptive design. Seven of the dose-finding studies referenced preclinical data to assist with initial 321 antivenom dosing.
322
There was a lack of consistency of clinical endpoints. Clearly defined efficacy and 323 toxicity endpoint outcomes were described in one randomised clinical trial of neurotoxic 324 snake-bite. In 13 papers with predominant haemotoxic venom, the clinical endpoints 325 used were clotting time (5), 20WBCT (5) prothrombin time (1), fibrinogen (1) available and easily modifiable for application to different contexts. In all the simulation 340 scenarios considered, the model based design converged to the simulation optimal dose 341 faster than the rule based design (Fig. 1) , including when the models used by the model 342 based design were mis-specified ( Fig. 1, panels 5-7) .
343
Simulation scenario 4 is the most likely scenario in the Myanmar context. In this 344 scenario, the antivenom has an MTD higher than its TED (improvement in 345 manufacturing techniques and quality control are anticipated to reduce toxicity), but 346 the TED is greater than the current recommended dose (80 mL). Therefore the starting 347 dose (120 mL) is too low compared to the simulation optimal dose (300 mL Fig. 3 shows the behaviour of the designs for scenario 1, whereby the starting dose is 358 in fact higher than the optimal dose, determined in this scenario by the MTD. This 359 scenario corresponds to the situation whereby the manufacturing of the antivenom is not 360 as good as reported (the reported low toxicity of the novel BPI antivenom in Myanmar 361 is from anecdotal evidence only) and causes frequent (approximately 10% occurrence) 362 toxicity at the starting dose in the adaptive arm. Convergence to approximately the 363 optimal dose occurs for the average trial under the model based design after 100 patients 364 are recruited. In comparison, the rule based design converges at a much slower rate.
365
Understanding how model mis-specification impacts the convergence of the model 366 based design is important for implementation. We simulated the stochastic behaviour of 367 the trial designs when (i) toxicity is not dose dependent (as argued by [33] ) and (ii) 368 when the distribution of venom mass is considerably different from a normal 369 approximation. In both of these settings, the model based designs outperforms the rule 370 based designs. In scenario 5, anaphylaxis occurred in 15% of patients independently of 371 Fig 1. Comparison between the model based design (blue) and the rule based design (red) across all simulation scenarios. Numbers correspond to the simulation scenario defined in the Methods section. In each panel, the thick lines (shaded areas) show the mean difference (95% interval of variation across trials) between the assigned doses and the simulation true optimal dose. Panels 1-4 show the results for the well-specified scenarios; panels 5-7 for the mis-specified scenarios. Note that each panel has a different y-axis range and the horizontal line shows the 0 y-axis value for reference. the dose administered. This is an extreme scenario but representative of a poorly 372 manufactured antivenom and serves to highlight how the designs adapt to this lack of 373 an underlying dose-response, which is a key assumption for both the rule based design 374 and the model based design. Under our definition of 'optimality', in this scenario, any 375 non-zero dose is above the MTD and therefore the optimal dose is 0 mL. Both the model 376 based design and the rule based design converge towards the minimum allowed dose (10 377 mL), but the convergence is much faster for the model based design (Figure 1, panel 5) . 378
Discussion
379
Antivenoms for the management of SBE have been subjected to few of the sequential 380 clinical studies required of new therapeutics for other diseases, both prior to and post 381 licensing. As a result, most antivenom dosing is based on animal models that are known 382 to extrapolate poorly to humans [30] . As for the development of many novel oncology 
390
Model based adaptive designs have clear benefits over the simpler rule based designs 391 such as the '3+3' design. The superior operating characteristics and greater efficiency 392 are well described in the literature [20] . Our simulations support this and we provide a 393 flexible model framework for antivenom dose-finding trials that wish to simultaneously 394 optimise efficacy whilst guaranteeing safety. By pre-specifying a MTT patient safety is 395 inherently built in to the study design. There is no current standardized methodology 396 for implementing antivenom clinical dose-finding trials. Establishing a standardized 397 methodology would improve quality of antivenom research, prevent duplication and 398 enable greater comparison and understanding of the relationship between dose, efficacy 399 and toxicity. The model based adaptive design described and illustrated in this paper 400 has the potential for widespread uptake in the design of trials of antivenom to treat 401 bites of other snake and venomous species resulting in coagulopathy, neurotoxicity and 402 local tissue effects. The design is dependent on consistent and clinically relevant efficacy 403 and toxicity endpoints. Clinically relevant efficacy endpoints for envenoming resulting 404 in coagulopathy include the 20WBCT (applicable to Myanmar where other clotting 405 assays are not available) and a clinically significant elevation in prothrombin time or Supplementary Table S1 ).
417
The mechanism of early anaphylactic reactions secondary to antivenom and 418 relationship to dose is poorly understood [35] . The lack of prior exposure to antivenom 419 in the majority of patients with anaphylactic reactions to antivenom and poor russelli before and after antivenom therapy [37] . The study demonstrated elevated 424 levels of complement activity and inflammatory mediators before antivenom and 425 subsequent rises in mast cell tryptase and histamine following antivenom in keeping 426 with mast cell degranulation. As described earlier, clinical trials in antivenom therapy 427 rarely define clear toxicity endpoints and are not powered to accurately characterise 428 rare events (i.e. those occurring in 5% or fewer patients). In the dose-finding trials 429 displayed in Supplementary Table S1 , six studies demonstrate a trend suggestive of a 430 dose-toxicity relationship [24, 25, [38] [39] [40] [41] , two studies show the opposite 431 relationship [42, 43] and the remaining eight studies do not report toxicity as an 432 outcome. An earlier study by Reid with large numbers of patients was suggestive of a 433 dose-toxicity relationship [44] . Our design hypothesises that toxicity is dose dependent 434 following a logistic curve as a function of the logarithm of the dose. We show that this 435 design is robust to mis-specification in this model, both when the simulation truth is 436 not logistic and when the anaphylactic reactions occur idiosyncratically with no 437 apparent dose toxicity relationship. However, care is needed in determining what is an 438 acceptable rate of toxicity in the trial (the MTT).
439
The Bayesian model based design is particularly pertinent to assessing the optimal 440 dose of BPI Viper Antivenom for Daboia siamensis envenoming in Myanmar. Daboia 441 siamensis envenoming remains a significant health burden in Myanmar resulting in 442 considerable morbidity and mortality [26, 45] . Fast identification of an efficacious and 443 safe dose means that few patients in the trial will be administered sub-optimal doses.
444
Indeed, using the incrementally accrued data during the study should result in a 445 comparatively low sample size. This is an important consideration given the rural 446 nature of envenoming and cost of study resources when using multiple sites. The 447 resultant description of dose-efficacy and dose-toxicity relationships will enable policy 448 makers to confidently choose a dose which provided satisfactory efficacy and is safe in 449 the large majority of patients.
450
The Bayesian model based adaptive design necessitates the specification of Bayesian 451 priors. Prior elicitation is difficult especially with limited numbers of published clinical 452 trials, lack of post marketing data and antivenom batch variability. It is important to 453 note that the priors do not need to be strongly informative but serve to minimise 454 stochasticity at the start of the trial. The lack of prior knowledge may result in setting 455 unrealistic values for the TED and the MTT. We note that this affects the Bayesian 456 model based design and the rule based design equally. To alleviate this concern we 457 propose interim analyses (after 50 and then 100 patients are enrolled) with the specific 458 purpose of re-evaluating the TED and the MTT for futility. An alternative to setting 459 hard thresholds for the TED and MTT is to use an EffTox dose-finding design [46, 47] . 460 This design necessitates the construction of utility contours which determine an explicit 461 trade-off between efficacy and toxicity. We chose not to use this design for this context 462 as it is was not possible to reach an agreement with clinical experts and because it made 463 a strict comparison with a rule based method impossible. However, the EffTox design 464 may be appropriate for other snakebite dose-finding trials. The well known 465 disadvantage of a model based design is the need for greater statistical support in the 466 study design and continuous support during subject enrolment to determine each 467 sequential adapted dose. The simulation scripts that we provide should serve to help 468 trial statisticians design Bayesian model based adaptive trials in different contexts. In 469 addition, the use of real-time electronic case reporting allows for remote, off-site 470 statistical support. We will use e-CRFs in the dose-finding study in Myanmar with 471 statistical support remote (Bangkok) from the study site.
472
The design of the study is only as good as the endpoint which determines the 473 treatment response. We acknowledge that using the 20WBCT as a surrogate marker of 474 envenoming at presentation, and then resolution of envenoming at 6 hours, introduces 475 errors for which the design cannot account for. For pragmatic reasons, we believe that 476 using the 20WBCT, as recommended in the national guidelines, best replicates everyday 477 SBE management in Myanmar. Future work is needed to develop more specific 478 pharmacodynamic markers of treatment efficacy in SBE from Russell's viper and 479 haemotoxic snakes more widely. February 1, 2020 20/21 model we choose the logistic (sigmoid) model, with the dose v (in mL, 10 mL is equal to 660 one vial) on the logarithmic scale (base 2 for visual simplicity).
661
The toxicity dose-response model takes the following form: 662 P (Y tox = 1|Dose = v) = e αtox+βtox log 2 v 1 + e αtox+βtox log 2 v (1)
where Y tox = 1 indicates a toxic event (analphylaxis as defined in the main protocol 663 section XX), 0 otherwise; v is the dose in mL. The parameters α tox and β tox can then 664 be chosen using the following 665
• We specify a prior estimate (range) of the expected proportion of individuals who 666 would experience an SAE if given only 1 vial of antivenom. α tox is the logit of this 667 number. We set this number to be 1/1000 (1/100 -1/100000).
668
• We specify a prior estimate (range) of the maximum tolerated dose. The 669 parameter β tox (range) can be derived conditional on the estimate (range) of α tox 670 by solving the logit equation. The prior MTD is estimated to be 400 mL (200 -671 800).
672
From the estimated ranges for these 2 parameters, we can then derive Bayesian 673 priors for (α tox , β tox ).
